- Home
- LOAN vs ANVS Comparison
LOAN vs ANVS Comparison
Compare LOAN & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOAN
- ANVS
- Stock Information
- Founded
- LOAN 1989
- ANVS 2008
- Country
- LOAN United States
- ANVS United States
- Employees
- LOAN N/A
- ANVS N/A
- Industry
- LOAN Real Estate Investment Trusts
- ANVS Biotechnology: Pharmaceutical Preparations
- Sector
- LOAN Real Estate
- ANVS Health Care
- Exchange
- LOAN Nasdaq
- ANVS Nasdaq
- Market Cap
- LOAN 50.7M
- ANVS 53.3M
- IPO Year
- LOAN 1999
- ANVS 2020
- Fundamental
- Price
- LOAN $4.49
- ANVS $3.79
- Analyst Decision
- LOAN
- ANVS Strong Buy
- Analyst Count
- LOAN 0
- ANVS 3
- Target Price
- LOAN N/A
- ANVS $13.50
- AVG Volume (30 Days)
- LOAN 43.3K
- ANVS 3.2M
- Earning Date
- LOAN 10-24-2025
- ANVS 11-12-2025
- Dividend Yield
- LOAN 10.36%
- ANVS N/A
- EPS Growth
- LOAN N/A
- ANVS N/A
- EPS
- LOAN 0.46
- ANVS N/A
- Revenue
- LOAN $7,138,128.00
- ANVS N/A
- Revenue This Year
- LOAN N/A
- ANVS N/A
- Revenue Next Year
- LOAN $4.47
- ANVS N/A
- P/E Ratio
- LOAN $9.59
- ANVS N/A
- Revenue Growth
- LOAN N/A
- ANVS N/A
- 52 Week Low
- LOAN $4.29
- ANVS $1.11
- 52 Week High
- LOAN $6.05
- ANVS $7.52
- Technical
- Relative Strength Index (RSI)
- LOAN 24.60
- ANVS 81.36
- Support Level
- LOAN $4.29
- ANVS $2.11
- Resistance Level
- LOAN $4.98
- ANVS $4.00
- Average True Range (ATR)
- LOAN 0.15
- ANVS 0.39
- MACD
- LOAN -0.04
- ANVS 0.18
- Stochastic Oscillator
- LOAN 19.06
- ANVS 90.00
About LOAN Manhattan Bridge Capital Inc
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.